1.
Product Overview
1.1.
Market Definition
1.2.
Scope of the Market
1.2.1.
Markets Covered
1.2.2.
Years Considered for
Study
1.2.3.
Key Market
Segmentations
2.
Research Methodology
2.1.
Objective of the Study
2.2.
Baseline Methodology
2.3.
Key Industry Partners
2.4.
Major Association and Secondary Sources
2.5.
Forecasting Methodology
2.6.
Data Triangulation & Validation
2.7.
Assumptions and Limitations
3.
Executive Summary
3.1.
Overview of the
Market
3.2.
Overview of Key
Market Segmentations
3.3.
Overview of Key
Market Players
3.4.
Overview of Key
Regions/Countries
3.5.
Overview of Market
Drivers, Challenges, Trends
4.
Voice of Customer
4.1.
Commonly Used Genetic Engineering Techniques
4.2.
Commonly Used Gene Editing Techniques
4.3.
Benefits of Using Genetic Engineering Tools
4.4.
Preference for Genetic Engineering Tools, By Therapeutic Area
4.5.
Barriers to Adoption of Genetic Engineering Tools
4.6.
Brand Awareness
5. Global Genetic
Engineering Tools Market Outlook
5.1.
Market Size & Forecast
5.1.1.
By Value
5.2.
Market Share & Forecast
5.2.1. By Type (Genome Scale Editing Tools v/s Genome Scale
Engineering Tools)
5.2.1.1.
Genome Scale Editing Tools
(CRISPR, MAGE, CRMAGE, CREATE, Others)
5.2.1.2.
Genome Scale Engineering
Tools (Promoter Engineering, Ribosomal Binding Site (RBS) Engineering,
Synthetic Small Regulatory RNA, Others)
5.2.2. By Therapeutic Area (Sickle Cell Disease, Heart Disease,
Diabetes, Alzheimer’s Disease, Obesity, Others)
5.2.3. By End User (Biotechnology & Pharmaceutical
Companies, Academic & Research Institutions, Others)
5.2.4.
By Company (2022)
5.2.5. By Region
5.3.
Market Map
5.3.1.
By Type
5.3.2.
By Therapeutic Area
5.3.3.
By End User
5.3.4.
By Region
6. North America Genetic
Engineering Tools Market Outlook
6.1.
Market Size & Forecast
6.1.1.
By Value
6.2.
Market Share & Forecast
6.2.1. By Type (Genome Scale Editing Tools v/s Genome Scale
Engineering Tools)
6.2.1.1.
Genome Scale Editing Tools
(CRISPR, MAGE, CRMAGE, CREATE, Others)
6.2.1.2.
Genome Scale Engineering
Tools (Promoter Engineering, Ribosomal Binding Site (RBS) Engineering,
Synthetic Small Regulatory RNA, Others)
6.2.2. By Therapeutic Area (Sickle Cell Disease, Heart Disease,
Diabetes, Alzheimer’s Disease, Obesity, Others)
6.2.3. By End User (Biotechnology & Pharmaceutical
Companies, Academic & Research Institutions, Others)
6.2.4.
By Country
6.3.
North America: Country Analysis
6.3.1.
United States Genetic Engineering Tools
Market Outlook
6.3.1.1.
Market Size & Forecast
6.3.1.1.1.
By Value
6.3.1.2.
Market Share & Forecast
6.3.1.2.1.
By Type
6.3.1.2.2.
By Therapeutic Area
6.3.1.2.3.
By End User
6.3.2.
Mexico Genetic Engineering Tools Market Outlook
6.3.2.1.
Market Size & Forecast
6.3.2.1.1.
By Value
6.3.2.2.
Market Share & Forecast
6.3.2.2.1.
By Type
6.3.2.2.2.
By Therapeutic Area
6.3.2.2.3.
By End User
6.3.3.
Canada Genetic Engineering Tools Market Outlook
6.3.3.1.
Market Size & Forecast
6.3.3.1.1.
By Value
6.3.3.2.
Market Share & Forecast
6.3.3.2.1.
By Type
6.3.3.2.2.
By Therapeutic Area
6.3.3.2.3.
By End User
7. Europe Genetic
Engineering Tools Market Outlook
7.1.
Market Size & Forecast
7.1.1.
By Value
7.2.
Market Share & Forecast
7.2.1. By Type (Genome Scale Editing Tools v/s Genome Scale
Engineering Tools)
7.2.1.1.
Genome Scale Editing Tools
(CRISPR, MAGE, CRMAGE, CREATE, Others)
7.2.1.2.
Genome Scale Engineering
Tools (Promoter Engineering, Ribosomal Binding Site (RBS) Engineering,
Synthetic Small Regulatory RNA, Others)
7.2.2. By Therapeutic Area (Sickle Cell Disease, Heart Disease,
Diabetes, Alzheimer’s Disease, Obesity, Others)
7.2.3. By End User (Biotechnology & Pharmaceutical
Companies, Academic & Research Institutions, Others)
7.2.4.
By Country
7.3.
Europe: Country Analysis
7.3.1.
France Genetic Engineering Tools Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Type
7.3.1.2.2.
By Therapeutic Area
7.3.1.2.3.
By End User
7.3.2.
Germany Genetic Engineering Tools Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Type
7.3.2.2.2.
By Therapeutic Area
7.3.2.2.3.
By End User
7.3.3.
United Kingdom Genetic Engineering Tools
Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Type
7.3.3.2.2.
By Therapeutic Area
7.3.3.2.3.
By End User
7.3.4.
Italy Genetic Engineering Tools Market Outlook
7.3.4.1.
Market Size & Forecast
7.3.4.1.1.
By Value
7.3.4.2.
Market Share & Forecast
7.3.4.2.1.
By Type
7.3.4.2.2.
By Therapeutic Area
7.3.4.2.3.
By End User
7.3.5.
Spain Genetic Engineering Tools Market Outlook
7.3.5.1.
Market Size & Forecast
7.3.5.1.1.
By Value
7.3.5.2.
Market Share & Forecast
7.3.5.2.1.
By Type
7.3.5.2.2.
By Therapeutic Area
7.3.5.2.3.
By End User
8. Asia-Pacific Genetic
Engineering Tools Market Outlook
8.1.
Market Size & Forecast
8.1.1.
By Value
8.2.
Market Share & Forecast
8.2.1. By Type (Genome Scale Editing Tools v/s Genome Scale
Engineering Tools)
8.2.1.1.
Genome Scale Editing Tools
(CRISPR, MAGE, CRMAGE, CREATE, Others)
8.2.1.2.
Genome Scale Engineering
Tools (Promoter Engineering, Ribosomal Binding Site (RBS) Engineering,
Synthetic Small Regulatory RNA, Others)
8.2.2. By Therapeutic Area (Sickle Cell Disease, Heart Disease,
Diabetes, Alzheimer’s Disease, Obesity, Others)
8.2.3. By End User (Biotechnology & Pharmaceutical
Companies, Academic & Research Institutions, Others)
8.2.4.
By Country
8.3.
Asia-Pacific: Country Analysis
8.3.1.
China Genetic Engineering Tools Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Type
8.3.1.2.2.
By Therapeutic Area
8.3.1.2.3.
By End User
8.3.2.
India Genetic Engineering Tools Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Type
8.3.2.2.2.
By Therapeutic Area
8.3.2.2.3.
By End User
8.3.3.
South Korea Genetic Engineering Tools Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Type
8.3.3.2.2.
By Therapeutic Area
8.3.3.2.3.
By End User
8.3.4.
Japan Genetic Engineering Tools Market Outlook
8.3.4.1.
Market Size & Forecast
8.3.4.1.1.
By Value
8.3.4.2.
Market Share & Forecast
8.3.4.2.1.
By Type
8.3.4.2.2.
By Therapeutic Area
8.3.4.2.3.
By End User
8.3.5.
Australia Genetic Engineering Tools Market Outlook
8.3.5.1.
Market Size & Forecast
8.3.5.1.1.
By Value
8.3.5.2.
Market Share & Forecast
8.3.5.2.1.
By Type
8.3.5.2.2.
By Therapeutic Area
8.3.5.2.3.
By End User
8.3.6.
Thailand Genetic Engineering Tools Market Outlook
8.3.6.1.
Market Size & Forecast
8.3.6.1.1.
By Value
8.3.6.2.
Market Share & Forecast
8.3.6.2.1.
By Type
8.3.6.2.2.
By Therapeutic Area
8.3.6.2.3.
By End User
8.3.7.
Singapore Genetic Engineering Tools Market Outlook
8.3.7.1.
Market Size & Forecast
8.3.7.1.1.
By Value
8.3.7.2.
Market Share & Forecast
8.3.7.2.1.
By Type
8.3.7.2.2.
By Therapeutic Area
8.3.7.2.3.
By End User
9. South America Genetic
Engineering Tools Market Outlook
9.1.
Market Size & Forecast
9.1.1.
By Value
9.2.
Market Share & Forecast
9.2.1. By Type (Genome Scale Editing Tools v/s Genome Scale
Engineering Tools)
9.2.1.1.
Genome Scale Editing Tools
(CRISPR, MAGE, CRMAGE, CREATE, Others)
9.2.1.2.
Genome Scale Engineering
Tools (Promoter Engineering, Ribosomal Binding Site (RBS) Engineering,
Synthetic Small Regulatory RNA, Others)
9.2.2. By Therapeutic Area (Sickle Cell Disease, Heart Disease,
Diabetes, Alzheimer’s Disease, Obesity, Others)
9.2.3. By End User (Biotechnology & Pharmaceutical
Companies, Academic & Research Institutions, Others)
9.2.4.
By Country
9.3.
South America: Country Analysis
9.3.1.
Brazil Genetic Engineering Tools Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Type
9.3.1.2.2.
By Therapeutic Area
9.3.1.2.3.
By End User
9.3.2.
Argentina Genetic Engineering Tools Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Type
9.3.2.2.2.
By Therapeutic Area
9.3.2.2.3.
By End User
9.3.3.
Colombia Genetic Engineering Tools Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Type
9.3.3.2.2.
By Therapeutic Area
9.3.3.2.3.
By End User
10. Middle East and
Africa Genetic Engineering Tools Market Outlook
10.1.
Market Size & Forecast
10.1.1.
By Value
10.2.
Market Share & Forecast
10.2.1. By Type (Genome Scale Editing Tools v/s Genome Scale
Engineering Tools)
10.2.1.1. Genome Scale Editing Tools (CRISPR, MAGE, CRMAGE, CREATE,
Others)
10.2.1.2. Genome Scale Engineering Tools (Promoter Engineering,
Ribosomal Binding Site (RBS) Engineering, Synthetic Small Regulatory RNA,
Others)
10.2.2. By Therapeutic Area (Sickle Cell Disease, Heart Disease,
Diabetes, Alzheimer’s Disease, Obesity, Others)
10.2.3. By End User (Biotechnology & Pharmaceutical
Companies, Academic & Research Institutions, Others)
10.2.4.
By Country
10.3.
MEA: Country Analysis
10.3.1.
South Africa Genetic Engineering Tools
Market Outlook
10.3.1.1.
Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2.
Market Share & Forecast
10.3.1.2.1.
By Type
10.3.1.2.2.
By Therapeutic Area
10.3.1.2.3.
By End User
10.3.2.
Saudi Arabia Genetic Engineering Tools
Market Outlook
10.3.2.1.
Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2.
Market Share & Forecast
10.3.2.2.1.
By Type
10.3.2.2.2.
By Therapeutic Area
10.3.2.2.3.
By End User
10.3.3.
UAE Genetic Engineering Tools Market Outlook
10.3.3.1.
Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2.
Market Share & Forecast
10.3.3.2.1.
By Type
10.3.3.2.2.
By Therapeutic Area
10.3.3.2.3.
By End User
10.3.4.
Israel Genetic Engineering Tools Market Outlook
10.3.4.1.
Market Size & Forecast
10.3.4.1.1.
By Value
10.3.4.2.
Market Share & Forecast
10.3.4.2.1.
By Type
10.3.4.2.2.
By Therapeutic Area
10.3.4.2.3.
By End User
11.
Market Dynamics
11.1.
Drivers
11.2.
Challenges
12.
Market Trends & Developments
12.1.
Recent Development
12.2.
Mergers &
Acquisitions
12.3.
Product Launches
13. Global
Genetic Engineering Tool Market: SWOT Analysis
14. Porter’s
Five Forces Analysis
14.1.
Competition in the
Industry
14.2.
Potential of New
Entrants
14.3.
Power of Suppliers
14.4.
Power of Customers
14.5.
Threat of Substitute
Products
15.
Competitive
Landscape
15.1.
Business Overview
15.2.
Product Offerings
15.3.
Recent Developments
15.4.
Financials (As
Reported)
15.5.
Key Personnel
15.6.
SWOT Analysis
15.6.1. Thermo Fisher
Scientific Inc
15.6.2. CRISPR Therapeutics
AG
15.6.3. Editas Medicine,
Inc.
15.6.4. Intellia
Therapeutics, Inc
15.6.5. Merck KGaA
15.6.6. Horizon Discovery
Ltd
15.6.7. GeneCopoeia Inc
15.6.8. Takara Bio Inc
15.6.9. Sangamo
Therapeutics, Inc.
15.6.10.
Genscript Biotech Corporation
16. Strategic Recommendations